Third quarter results highlight strong operational performance across key value drivers: YUPELRI® (revefenacin) net sales of $62.2 million, recognized by Viatris ...

Concluded targeted enrollment of Phase 3 INDIGO trial evaluating obexelimab for the treatment of Immunoglobulin G4-Related ...

The list extends into the pharma industry, including Pfizer, GSK, and Novo Nordisk. On 14 November, Eli Lilly became a part of this group, after an account using its name and logo sent out a Tweet ...

The new money means that iTeos can now fund its activities through 2027, including the start of multiple phase 3 studies of belrestotug in combination with GSK ... and Logos Capital, as well ...

Under deal terms, GSK will give Vesalius Therapeutics $80 million in upfront and equity payments to identify treatments for ...

GSK is paying $80 million to ink a multi-target neurodegenerative pact with Flagship-founded Vesalius Therapeutics that ...

GSK is the latest to turn its back on prominent ... a spokesperson told Fierce Pharma via email. “While individual members make their respective decisions annually on membership, BIO has never ...

DelveInsight's 'Multiple Sclerosis Pipeline Insight 2024' report provides comprehensive global coverage of pipeline multiple ...

In a report released today, Peter Welford from Jefferies downgraded GlaxoSmithKline (GSK – Research Report) to a Hold, with a price ...

GSK (GSK) plans to depart the biotechnology industry’s largest trade group, the Biotechnology Innovation Organization, STAT’s John Wilkerson, Lizzy Lawrence, Rachel Cohrs Zhang, and Sarah Owermohle ...

DelveInsight's Dermatological Drugs Market Insights report provides the current and forecast market analysis, individual ...

GSK has spent slightly more on lobbying this year compared with 2023. The company spent $3.87 million in the first three ...